Piper Jaffray Cos. upgraded Sarepta Therapeutics Inc (NASDAQ:SRPT) to Overweight in a statement released earlier today.
- Updated: September 19, 2016
Piper Jaffray Cos. has upgraded Sarepta Therapeutics Inc(NASDAQ:SRPT) to Overweight in a statement released on Monday September 19 2016.
Previously on Friday July 22 2016, Needham reported on Sarepta Therapeutics Inc(NASDAQ:SRPT) upped the target price from $20.00 to $26.00 that indicated a possible upside of 0.15%.
Only yesterday Sarepta Therapeutics Inc (NASDAQ:SRPT) traded 91.30% higher at $51.30. Sarepta Therapeutics Inc’s 50-day average is $26.16 and its two hundred day moving average is $20.47. The last close is up 163.13% from the 200-day moving average, compared with the S&P 500 Index which has fallen -0.01% over the same time. 29,541,278 shares of SRPT were exchanged, up from ann avg. volume of 2,328,380.
With a total market value of $0.0, Sarepta Therapeutics Inc has a 52 week low of $8.00 and a one-year high of $56.18 with a P/E ratio of 0.
In addition to Piper Jaffray Cos. reporting it’s price target, a total of 13 equity analysts have reported on Sarepta Therapeutics Inc. The one year target stock price is $20.77 with three analysts rating the company a strong buy, one analyst rating the stock a buy, five firms rating the stock a hold, four firms rating the company to underperform, and lastly one brokeragerating the company as sell.
General Company Details For Sarepta Therapeutics Inc (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company’s lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, and is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.